USV Launches Xenia Brand Range Following Empagliflozin Patent Expiry

New Delhi: Strengthening its
leadership in diabetes care, USV Pvt. Ltd. has announced the launch of its Xenia
brand range, following the recent patent expiry of Empagliflozin in India.
Xenia offers a comprehensive set of products designed for the effective
management of Type 2 Diabetes Mellitus (T2DM), heart failure, and chronic kidney disease.

The Xenia brand range will come in
a variety of portfolio options, including monotherapy and fixed-dose
combinations to cater to diverse patient needs. The lineup includes
formulations of Empagliflozin alone, as well as combinations with Metformin and
Sitagliptin, offering flexible treatment choices for clinicians and patients
alike.

The Xenia portfolio comprises five
key products designed to address varied treatment needs. It includes Xenia 10,
containing Empagliflozin 10 mg, and Xenia 25, containing Empagliflozin 25 mg as
monotherapy options. Additionally, the range offers Xenia M 12.5/500, combining
Empagliflozin 12.5 mg with Metformin 500 mg, and Xenia M 12.5/1000 ER, which
pairs Empagliflozin 12.5 mg with Metformin 1000 mg in an extended-release form.
The brand range also includes Xenia ST 25, a fixed dose combination of Empagliflozin
25 mg with Sitagliptin 100 mg.

The Xenia range has been
introduced across different price points. Xenia 10 is priced at ₹125 per pack,
Xenia 25 at ₹163.9, Xenia M 12.5/500 at ₹140, Xenia M 12.5/1000 ER at ₹165, and
Xenia ST 25 at ₹220.2.

Commenting on the launch,
Prashant Tewari, Managing Director, USV said, “India has over 101 million
people with Type 2 diabetes and 136 million with prediabetes. With Xenia, we
aim to expand access to modern diabetes
care.”

With the loss of exclusivity,
Empagliflozin and its combinations are
now available at significantly reduced prices, enhancing affordability. USV’s extensive
reach across metros, Tier I, II & III cities, corporate hospitals, and
e-pharmacies ensures Xenia‘s
accessibility nationwide, including rural areas.